Shareholder Mercedes Meyer will join the panel, “Looking Ahead: Surveying the Changing Life Sciences Policy Landscape and its Effect on IP Due Diligence,” at the ACI Life Sciences IP Due Diligence on Wednesday, December 4.
Mercedes and her co-panelists will provide insights into the shifting life sciences policy landscape. The panel will also cover:
- The impact of the Supreme Court’s decision in Loper Bright Enterprises v. Raimondo on regulatory agency determinations from the Food and Drug Administration (FDA), the US Patent and Trademark Office (USPTO), and the Federal Trade Commission (FTC)
- The significance of the FTC’s position on Orange Book delistings and how this may affect diligence reviews
- The impact of the government’s potential use of march-in rights on life sciences intellectual property and how this would affect IP value
- The impact of the PTO’s proposed rule on Terminal Disclaimers and the request for comments on the experimental use exception
- The Inflation Reduction Act and the challenges it presents to patent value
- Recent reforms to patent eligibility following the introduction of the Patent Eligibility Restoration Act
- Anticipation of the position of the next administration on life sciences IP rights, policies, and regulations
You can read more about this event by clicking here.
